Analysis of long term responses and their impact on outcomes in patients with chronic phase CML treated with four different TKI modalities – analysis of 5 prospective clinical trials

BACKGROUND: Several tyrosine kinase inhibitors (TKI) are available for treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). We analyzed long term response and compared outcomes of patients treated with 4 TKI modalities used as frontline therapy for CML-CP. METHODS: This is...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet Haematol
Hlavní autoři: Jain, Preetesh, Kantarjian, Hagop, Alattar, Mona Lisa, Jabbour, Elias, Sasaki, Koji, Gonzalez, Graciela Nogueras, Dellasala, Sara, Pierce, Sherry, Verstovsek, Srdan, Wierda, William, Borthakur, Gautam, Ravandi, Farhad, O’Brien, Susan, Cortes, Jorge
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4854752/
https://ncbi.nlm.nih.gov/pubmed/26687797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(15)00021-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky